Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AMGN Stock Forecast 2025-2026
$336.74
Current Price
$181.33B
Market Cap
Buy 14
Hold 15
Sell 3
Wall St Analyst Ratings
Distance to AMGN Price Targets
+18.8%
To High Target of $400.00
-6.5%
To Median Target of $315.00
-46.5%
To Low Target of $180.00
AMGN Price Momentum
+5.2%
1 Week Change
+13.8%
1 Month Change
+18.7%
1 Year Change
+29.2%
Year-to-Date Change
-2.6%
From 52W High of $345.84
+32.9%
From 52W Low of $253.30
📊 TOP ANALYST CALLS
Did AMGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Amgen is one of their latest high-conviction picks.
Latest AMGN Stock Price Targets & Analyst Predictions
Based on our analysis of 41 Wall Street analysts, AMGN has a neutral consensus with a median price target of $315.00 (ranging from $180.00 to $400.00). The overall analyst rating is Buy (7.2/10). Currently trading at $336.74, the median forecast implies a -6.5% downside. This outlook is supported by 14 Buy, 15 Hold, and 3 Sell ratings.
Conversely, the most conservative target is provided by Geoff Meacham at Barclays, suggesting a 46.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AMGN Analyst Ratings
14
Buy
15
Hold
3
Sell
AMGN Price Target Range
Low
$180.00
Average
$315.00
High
$400.00
Current: $336.74
Latest AMGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AMGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 6, 2025 | Cantor Fitzgerald | Carter Gould | Neutral | Maintains | $315.00 |
| Nov 5, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $300.00 |
| Nov 5, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $329.00 |
| Sep 26, 2025 | B of A Securities | Tim Anderson | Underperform | Maintains | $272.00 |
| Sep 3, 2025 | Raymond James | Gary Nachman | Market Perform | Assumes | $N/A |
| Aug 25, 2025 | Piper Sandler | David Amsellem | Overweight | Maintains | $342.00 |
| Aug 6, 2025 | UBS | Trung Huynh | Neutral | Maintains | $317.00 |
| Aug 6, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $333.00 |
| Aug 6, 2025 | Citigroup | Geoff Meacham | Neutral | Maintains | $310.00 |
| Jul 23, 2025 | B of A Securities | Tim Anderson | Underperform | Maintains | $261.00 |
| Jul 22, 2025 | Citigroup | Geoff Meacham | Neutral | Maintains | $305.00 |
| Jul 21, 2025 | UBS | Trung Huynh | Neutral | Maintains | $326.00 |
| Jun 27, 2025 | Piper Sandler | David Amsellem | Overweight | Reiterates | $328.00 |
| Jun 24, 2025 | Cantor Fitzgerald | Carter Gould | Neutral | Reiterates | $305.00 |
| May 20, 2025 | Guggenheim | Vamil Divan | Neutral | Assumes | $288.00 |
| May 16, 2025 | Piper Sandler | David Amsellem | Overweight | Maintains | $328.00 |
| May 7, 2025 | Mizuho | Salim Syed | Neutral | Maintains | $280.00 |
| May 2, 2025 | RBC Capital | Gregory Renza | Outperform | Maintains | $320.00 |
| May 2, 2025 | UBS | Trung Huynh | Neutral | Maintains | $315.00 |
| Apr 22, 2025 | Cantor Fitzgerald | Overweight | Initiates | $N/A |
Amgen Inc. (AMGN) Competitors
The following stocks are similar to Amgen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Amgen Inc. (AMGN) Financial Data
Amgen Inc. has a market capitalization of $181.33B with a P/E ratio of 26.0x. The company generates $35.97B in trailing twelve-month revenue with a 19.5% profit margin.
Revenue growth is +12.4% quarter-over-quarter, while maintaining an operating margin of +34.2% and return on equity of +81.7%.
Valuation Metrics
Market Cap
$181.33B
Enterprise Value
$226.07B
P/E Ratio
26.0x
PEG Ratio
1.9x
Price/Sales
5.0x
Growth & Margins
Revenue Growth (YoY)
+12.4%
Gross Margin
+67.8%
Operating Margin
+34.2%
Net Margin
+19.5%
EPS Growth
+13.6%
Financial Health
Cash/Price Ratio
+5.2%
Current Ratio
1.3x
Debt/Equity
567.5x
ROE
+81.7%
ROA
+7.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Amgen Inc. (AMGN) Business Model
About Amgen Inc.
What They Do
Leading biotechnology company focused on therapeutics.
Business Model
Amgen generates revenue through the discovery, development, and marketing of biologic medicines, leveraging its strong pipeline in critical therapeutic areas such as oncology and cardiovascular diseases. The company’s advanced technology platforms and scientific expertise enable it to create innovative treatments that are essential for patient care.
Additional Information
Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for its significant contributions to the biotech industry. The company has developed key products like Neulasta, Enbrel, and Prolia, and maintains a commitment to investing in research and manufacturing facilities to enhance healthcare solutions globally.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
28,000
CEO
Mr. Robert A. Bradway
Country
United States
IPO Year
1984
Website
www.amgen.comAmgen Inc. (AMGN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.
Nov 14, 2025
By Kinjel Shah
Analyst Blog
Latest News
Trade Tracker: Bill Baruch buys more Amgen
2 days ago
Quick Summary
Bill Baruch of Blue Line Capital discusses his recent purchase of Amgen on CNBC's "Halftime Report," where the Investment Committee also debates the biotech sector.
Why It Matters
Baruch's Amgen purchase signals confidence in biotech, potentially influencing market sentiment and investment strategies in the sector. Watch for shifts in biotech valuations.
Source: CNBC Television
Market Sentiment:
Positive
Quick Summary
Investors reacted positively to bullish commentary from a well-known stock picker featured on TV, indicating increased market optimism.
Why It Matters
New bullish commentary from a well-known stock picker may influence market sentiment, potentially driving stock prices up as investors react to positive forecasts.
Source: The Motley Fool
Market Sentiment:
Positive
Cramer's Stop Trading: Amgen
2 days ago
Quick Summary
Jim Cramer is monitoring Amgen's shares, indicating potential investor interest in the company.
Why It Matters
Amgen's stock performance could indicate potential investment opportunities, reflecting market sentiment and company developments that may impact share value.
Source: CNBC Television
Market Sentiment:
Neutral
2 Supercharged Dividend Stocks to Buy Now
2 days ago
Quick Summary
Amgen is showing strong performance and advancing its pipeline, while Gilead Sciences benefits from a solid core business and diversification initiatives.
Why It Matters
Amgen's resilience and pipeline advancement indicate potential growth, while Gilead's strong core and diversification may enhance stability, signaling positive investment opportunities in biotech.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Amgen's CEO announced that a new trial indicates their drug can reduce heart attack risk, addressing long-standing questions from investigators and patients.
Why It Matters
Amgen's drug showing promise in reducing heart attack risk could boost sales and market share, positively impacting stock performance and investor sentiment.
Source: CNBC
Market Sentiment:
Positive
Quick Summary
Amgen's CEO Bob Bradway discussed quarterly results and upcoming drug trials on 'Mad Money' with Jim Cramer, providing insights into the company's future developments.
Why It Matters
Amgen's quarterly results and drug trials can impact stock performance and investor sentiment, influencing future growth potential and market positioning.
Source: CNBC Television
Market Sentiment:
Neutral
Frequently Asked Questions About AMGN Stock
What is Amgen Inc.'s (AMGN) stock forecast for 2026?
Based on our analysis of 41 Wall Street analysts, Amgen Inc. (AMGN) has a median price target of $315.00. The highest price target is $400.00 and the lowest is $180.00.
Is AMGN stock a good investment in 2026?
According to current analyst ratings, AMGN has 14 Buy ratings, 15 Hold ratings, and 3 Sell ratings. The stock is currently trading at $336.74. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AMGN stock?
Wall Street analysts predict AMGN stock could reach $315.00 in the next 12 months. This represents a -6.5% decrease from the current price of $336.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Amgen Inc.'s business model?
Amgen generates revenue through the discovery, development, and marketing of biologic medicines, leveraging its strong pipeline in critical therapeutic areas such as oncology and cardiovascular diseases. The company’s advanced technology platforms and scientific expertise enable it to create innovative treatments that are essential for patient care.
What is the highest forecasted price for AMGN Amgen Inc.?
The highest price target for AMGN is $400.00 from at , which represents a 18.8% increase from the current price of $336.74.
What is the lowest forecasted price for AMGN Amgen Inc.?
The lowest price target for AMGN is $180.00 from Geoff Meacham at Barclays, which represents a -46.5% decrease from the current price of $336.74.
What is the overall AMGN consensus from analysts for Amgen Inc.?
The overall analyst consensus for AMGN is neutral. Out of 41 Wall Street analysts, 14 rate it as Buy, 15 as Hold, and 3 as Sell, with a median price target of $315.00.
How accurate are AMGN stock price projections?
Stock price projections, including those for Amgen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 16, 2025 12:58 AM UTC